Bibliography


Barnes, B. and D. Edge (1982), ‘The Interaction of Science and Technolo-
Bibliography

211

gy,' in B. Barnes and D. Edge (eds), Science in Context, Milton Keynes: Open University Press.


Bartley, M. (1990), 'Do We Need a Strong Programme in Medical Sociology?', Sociology of Health & Illness, 12, 371–90.

Bayer (Japan) Co. Ltd (1994), 'Doitsu de umare Nihon de sodatta Ca Kikkouyaku Nifedipine' (a Ca Antagonist which was born in Germany and brought up in Japan), Yakushigaku Zassi, 29, 279–80. (in Japanese)


wirksaamer Coronartherapeutika’ (Dihydropyridine, a New Group of Strongly Effective Drug for Coronary Care), *Naturwissenschaaften*, 58, 578. (in German)


British Thoracic Society, British Paediatric Association, Research Unit of the Royal College of Physicians of London, King’s Fund Centre, National Asthma Campaign, Royal College of General Practitioners, General Practitioners in Asthma Group, British Association of Accident and Emergency Medicine and British Paediatric Respiratory Group
Bibliography


Preparation of a New Class of Antibiotics and the Relation of Structure to Activity', *Journal of the American Chemical Society*, 84, 3401–2.


Cambridge: Cambridge University Press.
Dunlop, D. and R. Shanks (1968), ‘Selective Blockade of Adrenoceptive
Beta Receptors in the Heart', *British Journal of Pharmacology and Chemotherapy*, 32, 201–18.


Edkins, J. S. (1906), 'The Chemical Mechanism of Gastric Secretion', *Journal of Physiology*, 34, 133–44.

Elks, J. and G. H. Phillipps (1985), 'Discovery of a Family of Potent Topical
Anti-inflammatory Agents’, in S. M. Roberts and B. J. Price (eds), 
*Medicinal Chemistry: The Role of Organic Chemistry in Drug Research*, 

Elston, M. A. (1997), ‘Introduction: The Sociology of Medical Sciences and 
Technology,’ in M. A. Elston (ed.), *The Sociology of Medical Sciences 

Emerson Thomas, H., W. B. Kannel, T. R. Dawber and P. M. McNamara 
(1966), ‘Cholesterol–Phospholipid Ratio in the Prediction of Coronary 
Heart Disease: The Framingham Study’, *New England Journal of 
Medicine*, 274, 701–5.

M. A. Hughes, D. J. Farrar, C. Young, M. Jones, A. M. Hay, A. R. E. 
Trial Comparing Zoladex 3.6 mg Depot with Stilboestrol 3 mg/day in 
Advanced Prostate Cancer: Patient Characteristics, Response and 
Treatment Failures’, *European Journal of Cancer and Clinical Oncology*, 
23, 1239.

Endo, A. (1975), ‘Shin Seiri Kassei Bussitsu no Seizo-hou’ (Methods for the 
production of a new bioactive substance), *Japanese Patent (Tokukai)* 50- 

Endo, A. (1979), ‘Monacolin K, a New Hypocholesterolemic Agent that 
Specifically Inhibits 3-Hydroxy-3-Methylglutaryl Coenzyme A Reduct-

*Bio Industry*, 4, 651–8. (in Japanese)

Inhibitors’, *Igaku no Ayumi*, 157, 720–2. (in Japanese)

Endo, A. (1992), ‘The Discovery and Development of HMG-CoA Reductase 
Inhibitors’, *Journal of Lipid Research*, 33, 1569–82.


Endo, A. (1999), ‘A Scientist’s Dream, Microbes, and Discovery of A 
Miracle Drug “Statin” ’, mimeo.

Endo, A. (2001), ‘Details of the Discovery of HMG-CoA Reductase 

Endo, A., M. Kuroda and K. Tanzawa (1976a), ‘Competitive Inhibition of 
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase by ML-236A and 
ML-236B Fungal Metabolites, Having Hypocholesterolemic Activity’, 

Endo, A., M. Kuroda and Y. Tsujita (1976b), ‘ML-236A, ML-236B and 
ML-236C, New Inhibitors of Cholesterogenesis Produced by *Penicillium 


Fleckenstein, A., H. Tritthart, H. J. Döring and K. Y. Byon (1972), 'BAY a 1040 – ein hochaktiver Ca"++-antagonistischer Inhibitor der elektromechanischen Koppelungsprozesse im Warmblüter-Myokard' (BAY a
1040: A Highly Active Ca$^{++}$ Antagonistic Inhibitor of the Electro-mechanical Coupling Processes in the Warm-blooded Myocardium), *Arzneimittel Forschung (Drug Research)*, 22, 22–33. (in German)


Harper, A. A. (1946), ‘The Effect of Extracts of Gastric and Intestinal Mucosa on the Secretion of HCl by the Cat’s Stomach’, Journal of Physiology, 105, 31P.
Harris, G. W. (1955), Neural Control of the Pituitary Gland, London: Edward Arnold.
Hartley, D., D. Jack, L. H. C. Lunts and A. C. Ritchie (1968), ‘New Class of


Heino, M. (1994), ‘Regularly Inhaled \( \beta \)-Agonists with Steroids Are Not Harmful in Stable Asthma’, *Journal of Allergy and Clinical Immunology*, 93, 80–4.


Himori, N. and N. Taira (1977), ‘Assessment of the Selectivity of OPC-


Johnson, L. R. (1971), 'Control of Gastric Secretion: No Room for Histamine?', *Gastroenterology*, 61, 106–18.


Konzett, H. (1940a), ‘Neue broncholytisch hochwirksame Körper der Adrenalinreihe’ (New Highly Active Bronchodilating Substance of Adrenalin Series), Naunyn-Schmiedeberg’s Archiv für Experimentelle Pathologie und Pharmakologie, 197, 27–40. (in German)

Konzett, H. (1940b), ‘Neues zur Athmatherapie’ (News for the Asthma Therapy), Klinische Wochenschrift, 19, 1303–6. (in German)


Lal, S., D. M. Harris, K. K. Bhalla, S. N. Singhal and A. G. Butler (1972),


Larsson, S., N. Svedmyr and G. Thiringer (1977), 'Lack of Bronchial Beta Adrenoceptor Resistance in Asthmatics During Long-term Treatment with Terbutaline', *Journal of Allergy and Clinical Immunology*, 59, 93–100.


Lemay, A. and G. Quesnel (1982), 'Potential New Treatment of Endo-


Lundback, B., M. Alexander, J. Day, J. Herbert, R. Holzer, R. Van Uffelen,
S. Kesten and A. L. Jones (1993), ‘Evaluation of Fluticasone Propionate (500 μg day\(^{-1}\)) Administered Either as Dry Powder via a Diskhaler\(^\oplus\) Inhaler or Pressurized Inhaler and Compared with Beclomethasone Dipropionate (1000 μg day\(^{-1}\)) Administered by Pressurized Inhaler’, *Respiratory Medicine*, **87**, 609–20.


McIntosh, F. C. (1938), ‘Histamine as a Normal Stimulant of Gastric Secretion’, Quarterly Journal of Experimental Physiology and Cognate Medical Sciences, 28, 87–98.


Monahan, M. W., M. S. Amoss, H. A. Anderson and W. Vale (1973),
‘Synthetic Analogs of the Hypothalamic Luteinizing Hormone Releasing Factor with Increased Agonist or Antagonist Properties’, Biochemistry, 12, 4616–20.


Nakagawa, K., N, Murakami, S. Yoshizaki, M. Tominaga, H. Mori, Y.


Ogawa, Y. (1999), ‘R&D no Keii’ (the Details of R&D), a document given by Dr Yasuaki Ogawa.


Peel, E. T. and G. J. Gibson (1980), ‘Effects of Long-term Inhaled Salbuta-


Powles, R., E. Shinebourne and J. Hamer (1969), ‘Selective Cardiac Sympa-
thetic Blockade as an Adjunct to Bronchodilator Therapy’, *Thorax*, 24, 616–18.


Rothlin, E. and R. Gundlach (1921), 'Étude Expérimentionale de l'Influence de l'Histamine sur la Sécrétion Gastrique' (an Experimental Study of the Influences of Histamine on the Gastric Secretion), *Archives Internationales de Physiologie*, 17, 59–84. (in French)


Russell, S. and R. Williams (1988), 'Opening the Black Box and Closing It
Behind You: On Micro-sociology in the Social Analysis of Technology',
*Edinburgh PICT Working Paper* no. 3, Edinburgh: Research Centre for
Social Science, University of Edinburgh.

‘Effect of Nicardipine on Rest and Exercise Hemodynamics in Chronic
Congestive Heart Failure’, *American Journal of Cardiology*, 58, 583–8.

Saameli, K. (1967), ‘Comparative Studies with β-Receptor Blocking Agents

Sackett, D. L., H. S. Shannon and G. W. Brownman (1990), ‘Fenoterol and

Sacks, J., A. C. Ivy, J. P. Burgess and J. E. Vandolah (1932), ‘Histamine as
the Hormone for Gastric Secretion’, *American Journal of Physiology*,
101, 331–8.

Lewis (1984), ‘Controlled Release of a Luteinizing Hormone-releasing
Hormone Analogue from Poly (d,l-lactide-co-glycolide) Microspheres’,

*Clinical Endocrinology*, 18, 571–92.

Gonadotropin Inhibition by a Highly Active Analog of Luteinizing
Hormone Releasing Hormone’, *Fertility and Sterility*, 30, 205–9.


Santen, R. J., B. Warner, L. M. Demers, M. Dufau and J. A. Smith (1984a),
‘Leuprolide Therapy for Prostatic Carcinoma’, in B. H. Vickery, J. J.
Nestor and E. S. E. Hafez (eds), *LHRH and Its Analog*, Lancaster: MTP
Press, pp. 351–64.

‘Long Term Effects of Administration of a Gonadotropin-releasing
Hormone Superagonist Analog in Men with Prostatic Carcinoma’,
*Journal of Clinical Endocrinology and Metabolism*, 58, 397–400.

Competitive Biomedical R&D*, New York: Wiley-Liss.

Sato, A., A. Ogiso, H. Noguchi, S. Mitsui, I. Kaneko and Y. Shimada
(1980), ‘Mevalonolactone Derivatives as Inhibitors of 3-Hydroxy-3-
Methylglutaryl Coenzyme A Reductase’, *Chemistry and Pharmacology

Meites, B. T. Donovan and S. M. McCann (eds), *Pioneers in Neuro-


Scrip Yearbook (1991), Richmond, Surrey: PJB Publishing

Scrip Yearbook (1993), Richmond, Surrey: PJB Publishing


Takagi, T., M. Takeda and H. Maeno (1982), 'Effect of a New Potent H₂-Blocker, 3-[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N²-sulfamoylpropionamide (YM-11170) on Gastric Secretion Induced by Histamine and Food in Conscious Dogs', *Archives internationales de pharmacodynamie et de thérapie*, 256, 49–58.

Takayanagi, I., N. Kondo, H. Yamashita, T. Hongo and K. Takagi (1977),


Takenaka, T. (1974), '2, 6-Dimethyl-4-(3-nitrophenyl)-1, 4-dihydropyridine -3, 5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93) no Noujyunkan ni taisuru Sayo’, Kiso to Rinsyo (Clinical Report), 8, 51-64. (in Japanese)

Takenaka, T., S. Usuda, T. Nomura, H. Maeno and T. Sado (1976). 'Vasodilator Profile of a New 1, 4-Dihydropyridine Derivative, 2, 6-Dimethyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylic Acid 3-[2-(N-Benzyl-N-methylamino)]-ethyl Ester 5-Methyl Ester Hydrochloride (YC-93)', Arzneimittel Forschung (Drug Research), 26, 2172-8.


Princeton University Press.


Tsushima, S., M. Sendai, M. Shiraishi, M. Kato, N. Matsumoto, K. Naito


Vaughan Williams, E. M. (1966), 'Mode of Action of Beta Receptor Antag-


Wilding, P., M. Clark, J. T. Coon, S. Lewis, L. Rushton, J. Bennett, J.


Yakuji Handobukku (Handbook of Pharmaceutical Affairs) (1997), Tokyo:
Bibliography 259

Yakugyo Jihou Sya. (in Japanese)


